Observational studyHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2019
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Observational study in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Subclinical Atherosclerosis, Hyperlipidemia and New-Onset Diabetes Should Not Be Ignored Despite Initial Angiographic Exclusion of Significant Atherosclerotic Occlusive Arterial Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Assessing the Accuracy and Precision of Artificial Intelligence for Diabetes Mellitus and Hypertension Management.Journal of clinical medicine · 2026Article
- Gut Microbiota: Cardiovascular Disease Prevention and Targeted Therapies.Biomedicines · 2026Review
- Type A Aortic Dissection: From Diagnosis to Cardiac Rehabilitation.Journal of clinical medicine · 2026Review
- Cardiac Rehabilitation in Patients After Coronary Artery Bypass Grafting: Core Components and Long-Term Follow-Up.Journal of clinical medicine · 2026Review
- European Hypertension Guidelines: Similarities and What the Practicing Physician Should Keep in Mind.Journal of clinical medicine · 2026Review
- Cardiovascular disease risk assessment, exercise training, and management of complications in patients with chronic kidney disease.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
- Secondary Prevention After Acute Coronary Syndromes in Women: Tailored Management and Cardiac Rehabilitation.Journal of clinical medicine · 2025Review
- A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin/ezetimibe as single-pill combination vs. free combination in Italy.European heart journal open · 2024Article
- The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF.Journal of clinical medicine · 2023Review
- Present and Future of Dyslipidaemia Treatment-A Review.Journal of clinical medicine · 2023Review
- Hypertensive Heart Disease: A Narrative Review Series-Part 2: Macrostructural and Functional Abnormalities.Journal of clinical medicine · 2023Review
- Hypertensive Heart Failure.Journal of clinical medicine · 2023Review
- Different Trajectories for Diabetes Mellitus Onset and Recovery According to the Centralized Aerobic-Anaerobic Energy Balance Compensation Theory.Biomedicines · 2023Article
- Potentially Inappropriate Medications Use among Older Adults with Dyslipidaemia.Journal of clinical medicine · 2023Article
- Resting Blood Pressure in Master Athletes: Immune from Hypertension?Sports (Basel, Switzerland) · 2023Article
- Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention.Healthcare (Basel, Switzerland) · 2023Review
- Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development.International journal of environmental research and public health · 2022Review
- Fixed Versus Free Combinations Of Antihypertensive Drugs: Analyses Of Real-World Data Of Persistence With Therapy In Italy.Patient preference and adherence · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPolytherapy is often required to treat the comorbidity of hypertension and hyperlipidemia. Fixed-dose co-formulation, rather than free combinations, simplifies medication taking and also improves adherence to medication, which is the key for a successful management of these conditions.
aimTo determine the number of patients potentially eligible for treatment with triple fixed-dose atorvastatin/perindopril/amlodipine (CTAPA), and to estimate if an unmet medical need exists among CTAPA free combination treated patients.
methodsThis observational retrospective study was based on administrative databases of 3 Italian Local Health Units. The cohort comprised adult patients with at least one prescription of amlodipine and perindopril (either as free combination or co-formulated) and atorvastatin during 2014. Follow-up period started on the date of prescription of the 3 molecules (index date) and lasted 1 year. Adherence to CTAPA was analyzed during follow-up, by using the proportion of days covered (PDC).
results2292 patients (9.1 per 10,000 beneficiaries) had a prescription for CTAPA as free combination. Only 1249 (54.5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification. The number of patients with CTAPA increased during the study period. Discontinuation of drugs prescribed the year before interested 582 patients in 2014, and 522 in 2015. Considering the Italian national population (n = 60,782,668), it was estimated that 69,542 hypertensive patients could be eligible for fixed-dose CTAPA during 2014.
conclusionsReal-world analysis among patients with free combination therapy can be applied to estimate the eligible population for fixed combination, and to evaluate the appropriateness of their prescriptions. Moreover, fixed-dose CTAPA could effectively improve adherence, which was calculated to be low in the free combination cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.